调和汤治疗中轴型未分化脊柱关节炎38例临床观察

Clinical observation on treating 38 cases of axial undifferentiated spondyloarthritis with the Tiaohe decoction

目的:观察调和汤联合西药治疗中轴型未分化脊柱关节炎(Undifferentiated Spondyloarthritis,USpA)的临床疗效及探讨诊治思路。方法:78例USpA患者随机分为对照组38例和治疗组40例。对照组服用塞来昔布胶囊,治疗组在对照组治疗的基础上采用调和汤进行治疗。两组均治疗4周,比较治疗前后Bath强直性脊柱炎疾病活动指数(BASDAI)、Bath强直性脊柱炎疾病功能指数(BASFI)、Bath强直性脊柱炎测量指数(BASMI)、AS疾病活动度(ASDAS)、生活质量问卷(ASQoL)等评分的变化,并评价两组欧洲风湿病联盟和国际强直性脊柱炎评估工作组(ASAS)20、50的改善率。结果:两组治疗后BASDAI、BASFI、BASMI、ASDAS、ASQoL等评分均较治疗前改善,差异有统计学意义;两组治疗后组间比较,治疗组参数优于对照组,差异有统计学意义;第4周达到ASAS 20、50的患者,治疗组分别有28、20例,对照组有14、8例,差异有统计学意义(P<0.05)。结论:调和汤联合西药治疗中轴型未分化脊柱关节病优于单用西药组。

Objective:To observe the clinical efficacy of the Tiaohe decoction(调和汤)plus Western medicine on axial undifferentiated spondyloarthritis,and discuss diagnosis and treatment ideas.Methods:78 cases were randomly assigned to the control group of 38 cases and the treatment group of 40 cases.The control group took celecoxib capsules.The treatment group additionally took the Tiaohe decoction.The treatment course in both groups was 4 weeks.Results:The BASDAI,BASFI,BASMI,ASDAS and ASQoL in the groups were all ameliorated,with statistically significant differences(P<0.05).After treatment,the above indicators in the treatment group were better than the control group,and the difference was statistically significant.At 4th week after treatment,there were 28 cases of ASAS 20 and 20 cases of ASAS 50 in the treatment group,and 14 cases of ASAS 20 and 8 cases of ASAS 50 in the control group,P<0.05.Conclusion:The Tiaohe decoction plus celecoxib capsule showed better effects on axial undifferentiated spondyloarthritis than celecoxib capsule alone.